Levofloxacino Kern Pharma (Levofloxacin)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. Inhibiting these enzymes creates lethal DNA breaks, leading to rapid bactericidal activity against a broad spectrum of Gram‑negative and Gram‑positive bacteria.

The appropriate dose of levofloxacin is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local guidelines. Dosage regimens are individualized and should follow the prescriber’s order.

Safety data for levofloxacin in pregnancy and lactation are limited, and the drug is generally classified as contraindicated or to be used only when the benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Levofloxacino Kern Pharma, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Levofloxacin is the L‑isomer of ofloxacin and offers broader Gram‑positive coverage and higher lung penetration compared with ciprofloxacin. It is often preferred for respiratory infections, whereas ciprofloxacin is frequently used for urinary tract infections. Both share a similar safety profile, but individual patient factors and local resistance patterns guide selection.

Levofloxacino Kern Pharma should be stored below 25 °C in its original packaging, protected from moisture and light. The sterile vial must be kept in a clean, dry area and inspected for particulate matter before use. Do not freeze or expose to extreme temperatures.

Levofloxacino Kern Pharma is administered intravenously. The vial is reconstituted with the appropriate diluent and infused over a period recommended by the prescriber, typically 30‑60 minutes for a single dose. Infusion should be performed using aseptic technique and compatible IV sets.

Serious adverse events include tendon rupture or inflammation, QT‑interval prolongation that can precipitate arrhythmias, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Patients should be instructed to report sudden tendon pain, palpitations, or severe gastrointestinal symptoms immediately.

Levofloxacin is contraindicated in individuals with a known hypersensitivity to fluoroquinolones or any component of the formulation. It should be avoided in patients with a history of tendon disorders related to fluoroquinolone therapy, uncontrolled arrhythmias, or those taking other QT‑prolonging drugs without careful monitoring.